This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

Federal Circuit holds Novo Nordisk patent invalid


The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.

Novo Nordisk, Caraco, Federal Circuit


Payment types accepted